pur501

PUR501 is a novel, orally bioavailable small molecule that acts as a partial agonist of the serotonin 2A (5-HT2A) receptor. Developed by PurMinds NeuroPharma, PUR501 is designed to promote neuroplasticity without inducing hallucinations, distinguishing it from classic psychedelics. Preclinical studies have shown that PUR501 induces structural changes in neurons similar to those caused by psilocin but with minimal hallucinogenic effects and a favorable cardiac safety profile (low hERG inhibition and no serotonin 2B activation). The drug is being developed as a first-in-class neuroplastogen for neurological and neurodegenerative disorders, with mild cognitive disorder as an initial indication[1][2][3][4][5].